Obsidian Therapeutics announced a merger with Galera Therapeutics backed by a $350 million infusion to support cancer drug trials. The combined company structure includes a public listing and a private placement, intended to fund development across the pipeline while positioning Obsidian’s tumor-infiltrating lymphocyte (TIL) approach against incumbent TIL competitors. The deal narrative emphasizes comparative differentiation, with Obsidian aiming to show advantages over Iovance Biotherapeutics’ TIL therapy used in melanoma. By pooling development capabilities and capital, the merger is designed to accelerate clinical execution and help de-risk further trials. For the sector, the transaction reflects how TIL developers are seeking scale and financial runway to generate more robust comparative datasets and move faster from early signals to later-stage validation. The next milestones will be how the combined company prioritizes indications, trial designs, and manufacturing or logistics improvements that are often critical for cell therapy scalability.